Inhibikase Therapeutics Files Additional Proxy Materials
Ticker: IKT · Form: DEFA14A · Filed: Jun 21, 2024 · CIK: 1750149
Sentiment: neutral
Topics: proxy-filing, sec-filing, regulatory
Related Tickers: IKT
TL;DR
IKT filed more proxy docs, no fee. Shareholders need to review.
AI Summary
Inhibikase Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on June 21, 2024. This filing is related to their proxy statement and indicates no fee was required for this submission. The company is involved in the biological products sector and is incorporated in Delaware.
Why It Matters
This filing provides updated or supplementary information to shareholders regarding company matters, which is crucial for informed voting decisions at shareholder meetings.
Risk Assessment
Risk Level: low — This filing is a routine administrative submission for proxy materials and does not inherently represent new financial or operational risks.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- 0000950170-24-076301 (filing_id) — Accession Number
- 20240621 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Inhibikase Therapeutics, Inc.
When was this filing submitted?
The filing was submitted on June 21, 2024.
Was there a filing fee associated with this submission?
No, the filing indicates that no fee was required.
What is the company's primary business sector?
The company's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 121 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-06-21 16:30:10
Filing Documents
- ikt-proxy-special-2024_d.htm (DEFA14A) — 9KB
- img16462099_0.jpg (GRAPHIC) — 2900KB
- img16462099_1.jpg (GRAPHIC) — 1669KB
- 0000950170-24-076301.txt ( ) — 6294KB
From the Filing
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Inhibikase Therapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.